STOCK TITAN

Obsidian Therapeutics grants CFO 165K stock options

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Obsidian Therapeutics, Inc. (OBX) Chief Financial Officer Julie B. Feder received an option award covering 164,790 shares of common stock on August 3, 2026, with a $12-per-share exercise price and an August 2, 2036 expiration date. The option vests and becomes exercisable in 16 equal quarterly installments, beginning January 12, 2027; the second installment is February 3, 2027, with the remaining installments each quarter thereafter, subject to Feder’s continued service on each vesting date.

Insider Feder Julie B
Role Chief Financial Officer
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) F1 164,790 $0.00 $0.00
Holdings After Transaction: Stock Option (Right to Buy) — 164,790 options (Direct)
Footnotes (1)
  1. F1. The shares underlying this option shall vest and become exercisable in sixteen (16) equal quarterly installments, with the first installment vesting on January 12, 2027, the second installment vesting on February 3, 2027, and the remaining installments vesting each quarter thereafter, subject to the Reporting Person's continued service with the Issuer on such vesting date.
Underlying common shares 164,790 shares Covered by the option award dated August 3, 2026
Exercise price $12 per share Option award
Vesting installments 16 equal quarterly installments Subject to continued service on each vesting date
First vesting date January 12, 2027 First installment
Second vesting date February 3, 2027 Second installment
Expiration date August 2, 2036 Option award
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy)"
quarterly installments technical
"sixteen (16) equal quarterly installments"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What option award did Obsidian Therapeutics (OBX) CFO Julie B. Feder receive?

Julie B. Feder received an option award covering 164,790 common shares on August 3, 2026, with an exercise price of $12 per share and an expiration date of August 2, 2036.

When do Julie B. Feder’s OBX options vest?

The options vest in 16 equal quarterly installments. The first installment is scheduled for January 12, 2027, the second for February 3, 2027, and the remaining installments each quarter thereafter, subject to her continued service on each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Feder Julie B

(Last)(First)(Middle)
C/O OBSIDIAN THERAPEUTICS, INC.
1030 MASSACHUSETTS AVE

(Street)
CAMBRIDGE MASSACHUSETTS 02138

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Obsidian Therapeutics, Inc. [ OBX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/03/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$1208/03/2026A164,790 (1)08/02/2036Common Stock164,790$0164,790D
Explanation of Responses:
1. The shares underlying this option shall vest and become exercisable in sixteen (16) equal quarterly installments, with the first installment vesting on January 12, 2027, the second installment vesting on February 3, 2027, and the remaining installments vesting each quarter thereafter, subject to the Reporting Person's continued service with the Issuer on such vesting date.
/s/ Gabriela Morales-Rivera, Attorney-in-Fact11/13/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading